US Drug Policies Could Cost Swiss Pharma Billions

A new industry-backed analysis is raising concerns about the long-term consequences of evolving US pharmaceutical trade and pricing policies, warning that Switzerland’s globally significant life sciences sector could face tens of billions of francs in economic losses over the coming decades.

The report, commissioned by the Swiss pharmaceutical industry and released amid growing uncertainty surrounding American healthcare and trade policy, estimates that the cumulative impact on Switzerland’s pharmaceutical ecosystem could approach CHF95 billion ($117 billion) by 2040 under certain scenarios. Researchers behind the study argue that a combination of drug-pricing reforms, tariff threats and shifting market incentives in the United States could alter investment decisions, reduce exports and affect future research activity.

The warning underscores the importance of the US market to Switzerland’s pharmaceutical industry. Switzerland is home to some of the world’s largest drugmakers, including Novartis and Roche, while pharmaceutical and chemical products account for more than half of Swiss exports. Any major change in American healthcare policy therefore has implications extending well beyond corporate earnings and into the broader Swiss economy.

According to the study, the concern is not limited to tariffs alone. Researchers examined a range of US initiatives aimed at reducing domestic drug costs and encouraging pharmaceutical manufacturing within the United States. Industry groups argue that these policies may reshape where companies choose to launch medicines, conduct research or expand production facilities.

Recent developments have intensified those concerns. The Trump administration has continued pursuing policies designed to lower medicine prices for American consumers while encouraging pharmaceutical companies to expand domestic manufacturing. Proposed tariff measures on imported medicines and efforts to link US drug prices more closely to prices in other countries have become central points of debate within the global pharmaceutical industry.

Industry representatives argue that such measures could create unintended consequences for innovation and patient access. A recent survey by Swiss pharmaceutical association Interpharma found that some companies have become more cautious about launching new medicines in Switzerland because lower Swiss prices could influence future US price comparisons. The organization reported a decline in reimbursement applications for innovative medicines and warned that Swiss patients could face delays in access to certain new treatments.

The issue highlights the increasingly global nature of pharmaceutical pricing. Drug manufacturers frequently consider multiple markets when setting prices and planning product launches. Changes in one major market—particularly the United States, which remains the world’s largest pharmaceutical market—can influence commercial strategies across numerous countries.

Supporters of US reforms argue that Americans have long paid higher prices for medicines than consumers in many other developed countries and that reforms are necessary to reduce healthcare costs. Advocates of stronger pricing measures also contend that foreign governments often benefit from lower prices while American patients bear a disproportionate share of pharmaceutical innovation costs. These arguments have increasingly shaped trade and healthcare discussions in Washington.

For Switzerland, however, the debate carries particular significance. The pharmaceutical industry represents one of the country’s most important economic sectors, providing high-skilled employment, supporting research institutions and generating substantial export revenue. Any reduction in industry investment could have ripple effects throughout the Swiss economy, from laboratory research and biotechnology startups to manufacturing facilities and logistics networks.

Analysts note that the sector is already navigating a period of significant geopolitical uncertainty. Beyond pricing reforms, companies are evaluating supply-chain resilience, manufacturing locations and trade risks. Several pharmaceutical firms have announced plans to increase investments in the United States in response to evolving policy signals, while governments in Europe continue to assess how to maintain competitiveness in the life sciences sector.

The study also raises broader questions about the relationship between healthcare affordability and pharmaceutical innovation. Industry groups warn that reduced revenues could eventually affect research spending and the development of future therapies. Critics of that argument counter that pharmaceutical companies remain highly profitable and that lower prices could improve access to medicines without significantly undermining innovation. The balance between those competing objectives remains at the center of global healthcare policy debates.

While the report presents a long-term projection rather than a forecast of guaranteed outcomes, it reflects growing anxiety within one of Switzerland’s most strategically important industries. The findings arrive at a time when governments on both sides of the Atlantic are reassessing healthcare spending, industrial policy and trade relationships.

Whether the projected losses ultimately materialize will depend on the final shape of US policy decisions, the response of pharmaceutical companies and broader market conditions in the years ahead. What is already evident, however, is that decisions made in Washington are increasingly influencing strategic planning far beyond US borders. For Switzerland’s pharmaceutical sector, the stakes are especially high given its central role in the national economy and its deep integration into global healthcare markets.